Literature DB >> 1390249

Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment.

G Birgegård1, L Wide.   

Abstract

Serum erythropoietin (S-Epo) was measured with a radiommunoassay method in 36 patients with polycythaemia vera, 17 patients with secondary polycythaemia and 14 patients with relative polycythaemia. The diagnoses were made without the aid of the S-Epo values. It was found that S-Epo was below the reference range in 34/36 patients with polycythaemia vera (mean 2.1 +/- 1.0 U/l), elevated in all cases of secondary polycythaemia (mean 121.7 +/- 242 U/l) and normal in all but one of the cases with relative polycythaemia (mean 7.0 +/- 2.5 U/l). Previous studies of S-Epo levels in the differential diagnosis of polycythaemia have shown significant differences between the means of the groups but a considerable overlap. After phlebotomy treatment to normal haematocrit levels, the S-Epo levels remained subnormal in most of the polycythaemia vera patients even after 18 months at a haematocrit around 45%. Two patients who had been kept at normal haematocrit for 6 and 7 years both had subnormal S-Epo. We conclude that with an Epo assay method of high sensitivity and specificity it is possible to differentiate between different forms of polycythaemia with a high degree of certainty, even between patients with relative polycythaemia and polycythaemia vera patients. The reason why S-Epo remains low in spite of a normal haematocrit in treated polycythaemia vera patients is not known.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1390249     DOI: 10.1111/j.1365-2141.1992.tb02999.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Diagnosis of polycythaemia.

Authors:  M Messinezy; T C Pearson
Journal:  J Clin Pathol       Date:  1998-01       Impact factor: 3.411

2.  Vertebral artery thrombosis: a rare presentation of primary polycythaemia.

Authors:  H L Gul; S Y M Lau; D Chan-Lam; J-P Ng
Journal:  BMJ Case Rep       Date:  2014-05-26

3.  JAK2 V617F and the evolving paradigm of polycythemia vera.

Authors:  Robert T Means
Journal:  Korean J Hematol       Date:  2010-06-30

Review 4.  Cytokine-mediated communication: a quantitative appraisal of immune complexity.

Authors:  Grégoire Altan-Bonnet; Ratnadeep Mukherjee
Journal:  Nat Rev Immunol       Date:  2019-04       Impact factor: 53.106

5.  The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

6.  New automated chemiluminescent assay for erythropoietin.

Authors:  E W Benson; R Hardy; C Chaffin; C A Robinson; R J Konrad
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

7.  Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

Authors:  Hajime Akada; Dongqing Yan; Haiying Zou; Steven Fiering; Robert E Hutchison; M Golam Mohi
Journal:  Blood       Date:  2010-03-02       Impact factor: 22.113

Review 8.  Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).

Authors:  Jan Jacques Michiels; Juergen Thiele
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

9.  A truncating mutation in EPOR leads to hypo-responsiveness to erythropoietin with normal haemoglobin.

Authors:  Gudjon R Oskarsson; Ragnar P Kristjansson; Amy L Lee; Gardar Sveinbjornsson; Magnus K Magnusson; Erna V Ivarsdottir; Stefania Benonisdottir; Asmundur Oddsson; Olafur B Davidsson; Jona Saemundsdottir; Gisli H Halldorsson; Joseph Arthur; Gudny A Arnadottir; Gisli Masson; Brynjar O Jensson; Hilma Holm; Isleifur Olafsson; Pall T Onundarson; Daniel F Gudbjartsson; Gudmundur L Norddahl; Unnur Thorsteinsdottir; Patrick Sulem; Kari Stefansson
Journal:  Commun Biol       Date:  2018-05-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.